Scarica l'app Stockscreener
18.26
1.50%
0.27
Dopo l'orario di chiusura:
18.54
0.28
+1.53%
Uniqure N V Borsa (QURE) Ultime notizie
UniQure N.V. (QURE): RBC Capital Upgrades Rating to Outperform With Significant Upside Potential - 富途牛牛
uniQure (QURE) Stock Soars 36% as FDA’s Vinay Prasad Plans April Exit - MEXC
QURE INVESTOR ALERT: uniQure Faces Securities Class Action - GlobeNewswire
Levi & Korsinsky Notifies Shareholders of uniQure N.V.(QURE) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire Inc.
QURE Gains Momentum with Chardan Capital's Increased Price Target | QURE Stock News - GuruFocus
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
What the Options Market Tells Us About uniQure - Benzinga
Dragomir News: UniQure’s Price Volatility Amidst FDA Comments and Dr. Prasad’s Departure - timothysykes.com
FinancialContentQURE DEADLINE: Investors of uniQure N.V. (QURE) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on April 13, 2026 - FinancialContent
Wells Fargo Upgrades uniQure (QURE) with Significant Price Targe - GuruFocus
QURE: RBC Capital Upgrades uniQure with a Significant Price Targ - GuruFocus
UniQure (QURE) Shares Surge Following FDA Official's Departure - GuruFocus
uniQure stock jolts higher again after FDA biologics chief set to exit - TechStock²
uniQure (QURE) Receives Upgrades and Sees Pre-Market Boost - GuruFocus
Biotech firm stocks rise on FDA vaccine head’s exit (QURE:NASDAQ) - Seeking Alpha
uniQure (QURE) Stock Surges 36% After FDA Official Vinay Prasad Announces Departure - CoinCentral
uniQure surges following departure of key FDA official - Seeking Alpha
Confusion grows amid uniQure and FDA’s AMT-130 row - The Pharma Letter
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Wells Fargo Upgrades UniQure NV(QURE.US) to Buy Rating, Raises Target Price to $60 - 富途牛牛
RBC Capital Upgrades uniQure to Outperform From Sector Perform, Adjusts Price Target to $35 From $11, Keeps Speculative Risk - marketscreener.com
Why Is uniQure Stock Skyrocketing Monday? - Benzinga
Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike—Hims & Hers, Ovintiv, Uniqure In FocusState Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga
uniQure NV Opens Weak with 12.86% Gap Down Amid Market Concerns - Markets Mojo
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP; April 13, 2026, Lead Plaintiff Deadline - FinancialContent
Shifting Narrative For uniQure (QURE) As FDA Trial Demands Reshape AMT-130 Expectations - Yahoo Finance
uniQure NV Hits Day Low of $15.51 Amid Price Pressure - Markets Mojo
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, A LEADING LAW FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline – Company AnnouncementFT.com - Financial Times
Investors of uniQure N.V. (QURE) Seeking RecoveryContact Kaplan Fox Before Deadline on April 13, 2026 - FinancialContent
Biotech Stock QURE Once Tagged ‘Failed Product’ — CEO Sold Shares Days Before Rally - Stocktwits
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - PR Newswire
Insider Selling: uniQure (NASDAQ:QURE) Insider Sells 3,412 Shares of Stock - MarketBeat
uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 12,000 Shares - MarketBeat
UPCOMING DEADLINE: uniQure N.V. (QURE) Securities Fraud Class Action – April 13, 2026 Lead ... - Bluefield Daily Telegraph
UPCOMING DEADLINE: uniQure N.V. (QURE) Securities Fraud - GlobeNewswire
uniQure N.V. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ... - Bluefield Daily Telegraph
uniQure N.V. Sued for Securities Law Violations – Investors - GlobeNewswire
FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
QURE Stock Crashes 32% in a Week: Here's What You Should Know - Yahoo Finance
FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial - Sahm
Is US FDA Following Correct Precedent With UniQure Gene Therapy Randomized Trial Demand? - Citeline News & Insights
uniQure (QURE) Faces FDA Demand for Phase 3 Trial for Huntington's Drug - GuruFocus
uniQure used 'distorted comparison' in Huntington's asset trial: FDA official - Seeking Alpha
Kaplan Fox Encourages Investors of uniQure N.V. (QURE) to Contact the Firm Before Lead Plaintiff Deadline on April 13, 2026 - NewMediaWire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
Holzer & Holzer, LLC Reminds QURE Investors of the April - GlobeNewswire
UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official - marketscreener.com
uniQure's (QURE) Gene Therapy for Huntington's Disease Faces FDA Setback - GuruFocus
uniQure (NASDAQ:QURE) Shares Up 12%Here's Why - MarketBeat
FDA official calls UniQure's Huntington's disease treatment a failure - marketscreener.com
U.S. FDA official says uniQure is likely the latest company to make a failed therapy for Huntington's patients - marketscreener.com
US-listed shares of uniQure NV rise nearly 20% - marketscreener.com
What's Going On With uniQure Stock On Thursday?uniQure (NASDAQ:QURE) - Benzinga
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
UniQure (QURE) Faces FDA Hurdle for Huntington's Disease Therapy - GuruFocus
FDA Push for Fake Brain Surgery Trial Spurs Ethical Concerns - Bloomberg
QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 – Company AnnouncementFT.com - Financial Times
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of ... - Bluefield Daily Telegraph
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
The extremism of the FDA’s Marks and Prasad has come with costs - statnews.com
0.28%
17.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):